An ongoing dialogue on HIV/AIDS, infectious diseases,
July 29th, 2008
Antiretroviral Rounds: Immediate ART After an OI — Are We There Yet?
A few things have been guaranteed to get widely divergent views among HIV specialists — and one of them was when to start antiretroviral therapy in someone presenting with an acute OI. However, in the latest Antiretroviral Rounds, our two experts (Raphy Landovitz and Phil Grant/Andrew Zolopa) kind of agreed. They’d start immediately.
At least that’s what they said. What do we do? What do you do?
Categories: Antiretroviral Rounds, HIV, Infectious Diseases, Patient Care
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
3 Responses to “Antiretroviral Rounds: Immediate ART After an OI — Are We There Yet?”

Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
-
-
From the Blog — Most Recent Articles
- My Dog Louie, the Best Dog Ever, Is Seriously Ill September 26, 2025
- Two Drugs, Not Three: The DOLCE Study in Advanced HIV Disease September 19, 2025
- When Required Learning Modules Surprise You (In a Good Way) September 10, 2025
- End-of-Summer Musings — Hepatitis B, Dalbavancin, Alpha-Gal, and More September 4, 2025
- Watching the Chaos at the CDC — with Sadness and Alarm August 29, 2025
NEJM Journal Watch — Recent Infectious Disease Articles
- Can Recombinant Technology Improve Rabies Prevention?
- Is the High-Dose Flu Vaccine Better Than the Standard Dose for Preventing Severe Outcomes?
- Observations from ID and Beyond: Two Drugs, Not Three — The DOLCE Study in Advanced HIV Disease
- Marburg Outbreak! Can Rapid Response Minimize Mortality and Halt Spread?
- The Ryan White HIV/AIDS Program: Critical to Efforts to End the HIV Epidemic
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
I never start with Atripla per se, but split it as Truvada plus Sustiva for the first month or so, in case pt doesn’t tolerate efavirenz side effects.
Practicing in New York city I see many patients similar to the case that was described.
The immediate versus delayed initiation of ART in my view should depend on CD4 count. I may start ART in a patient with CD4>100 earlier than the one with CD4<50.
The lower the CD4 count the more chance of other hidden OIs . These infections should be screened first before initiating ART . This can be done safely in 2-4 weeks with special screening for significant OIs like CMV, crypt, etc….
This lag in initiation of ART and the medication/s needed for treatment of thepresenting OI while screening for other OIs also safeguard us against complexity of overlapping side effects by introducing the medications stepwise. Patient tolerance improves and compliance improves as well.
Excellent site, keep up the good work